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Abstract
Background: Ischemia-reperfusion (I/R) injury associated with living donor liver transplantation impairs liver graft
regeneration. Mesenchymal stem cells (MSCs) are potential cell therapeutic targets for liver disease. In this study, we
demonstrate the impact of MSCs against hepatic I/R injury and hepatectomy.
Methodology/Principal Findings: We used a new rat model in which major hepatectomy with I/R injury was performed.
Male Lewis rats were separated into two groups: an MSC group given MSCs after reperfusion as treatment, and a Control
group given phosphate-buffered saline after reperfusion as placebo. The results of liver function tests, pathologic changes
in the liver, and the remnant liver regeneration rate were assessed. The fate of transplanted MSCs in the luciferase-
expressing rats was examined by in vivo luminescent imaging. The MSC group showed peak luciferase activity of
transplanted MSCs in the remnant liver 24 h after reperfusion, after which luciferase activity gradually declined. The
elevation of serum alanine transaminase levels was significantly reduced by MSC injection. Histopathological findings
showed that vacuolar change was lower in the MSC group compared to the Control group. In addition, a significantly lower
percentage of TUNEL-positive cells was observed in the MSC group compared with the controls. Remnant liver regeneration
rate was accelerated in the MSC group.
Conclusions/Significance: These data suggest that MSC transplantation provides trophic support to the I/R-injured liver by
inhibiting hepatocellular apoptosis and by stimulating regeneration.
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Introduction
Liver transplantation is one of the most efficient treatments
available for various end-stage hepatic diseases. However, one of
the major limitations of liver transplantation is the scarcity of
donor organs. To overcome this limitation, split liver transplan-
tation or living donor liver transplantation are performed and
show the most promising outcomes. However, when these
treatments are performed in adult recipients with adult living
donors, size mismatch between graft and recipient becomes a
critical problem. The first priority is donor safety, and so smaller
sized grafts such as the left-lobe of the liver seem to be the optimal
choice [1].
Liver transplantation does inevitably lead to hepatic ischemia-
reperfusion (I/R) injury. Primary graft non-function or dysfunc-
tion, which occurs as a result of combined I/R injury and
secondary tissue regeneration impairment, remains a serious
complication in the clinical practice, and this is especially
the case for transplantation of livers that are small-for-size
[2,3]. Therefore, many studies have tried to elucidate the
mechanisms of I/R injury by means of appropriate in vivo
models. Effective treatment strategies aimed at reducing hepatic
I/R injury and accelerating liver regeneration could offer major
benefits in liver transplantations involving size mismatch of graft
and recipient.
Recent reports have demonstrated the capacity of mesenchymal
stem cells (MSCs) to specifically be involved in the repair of organ
tissue. These results indicate that MSCs are an attractive cell
source for regenerative medicine. As for the liver, most animal
studies have been carried out in drug-induced rodent models
[4,5,6]. However, the role of MSCs in hepatic I/R injury remains
to be established.
Here, we show that transplanted MSCs are able to ameliorate
hepatic I/R injury and significantly improve liver regeneration.
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Characterization of BM-MSCs
Bone marrow-derived mesenchymal stem cells (BM-MSCs)
were spindle shaped and plastic-adherent cells in standard culture
conditions (Figure 1A). BM-MSCs were characterized by
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2 on BM-MSCs by immunostaining
(Figure 1B, 1C, 1D, 1E). Previous data showed that rat MSCs
were positive for CD29 and CD105, but were negative for CD31
and CD34 [7,8]. Differentiation ability of BM-MSCs into
classical mesenchymal lineage cells including adipocytes, osteo-
blasts, or chondrocytes was verified by using previously reported
methods (Figure 2). The results indicated that the cells were
undifferentiated and had stem cell characteristics.
Effect of BM-MSCs on increased levels of serum ALT
induced by I/R in rats
Serum AST and ALT levels were measured to determine
damage to hepatocytes 24 h after reperfusion. Serum ALT
levels were significantly decreased in the MSC group com-
pared with the Control group (MSC group: 11366325 IU/L,
Control group: 21986854 IU/L, P,0.03). Serum AST levels
were also decreased (MSC group: 10436223 IU/L, Control
group: 13776428 IU/L, but not significantly). However, liver
sections of the MSC group were not morphologically dis-
tinguishable (H&E) from sections of the Control group (data
not shown).
Decreased luciferase activity in MSC rats
Twenty-four hours after reperfusion, most of the MSCs were
detected in the remnant liver by In Vivo Imaging System (IVIS),
and thereafter, luciferase activity diminished with time (Figure 3).
When luciferase was measured 168 h after reperfusion, the
amount of light emitted was only slightly detectable.
BM-MSC transplantation inhibits apoptosis after I/R injury
TUNEL-positive hepatocytes in the Control group were mainly
localized in the centrilobular region (Figure 4A). The extent of
hepatocyte apoptosis was evaluated by TUNEL staining 6 h after
reperfusion. TUNEL staining yielded a mean of 10.560.7
positively stained cells/high power field in the Control group,
and 0.560.5 in the MSC group (P,0.03) (Figure 4C).
X-gal immunostaining reveals localization of BM-MSCs in
the liver
Almost all of the LacZ-positive BM-MSCs were distributed
around the portal triad and interlobular connective tissue 6 h after
reperfusion (Figure 5A). There were very few LacZ-positive BM-
MSCs in the centrilobular region. When the periportal area was
examined more closely, BM-MSCs were also detected in the
sinusoids (Figure 5B).




+.A . Bright-field image. B–C. CD29 and CD105
surface antigens are positive. D. CD31 surfice antigen is negative, E. CD34 surfice antigen negative.
doi:10.1371/journal.pone.0019195.g001
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regeneration
After the operative procedure, all of the rats survived until
sacrifice. Seven-two hours after reperfusion, H&E staining
revealed significant morphological changes in Suzuki scores
(1.461.3 vs. 3.961.7, p,0.03) and necrosis scores (0.360.5 vs.
1.561.2, p,0.05) in the MSC group compared with the Control
group (Figure 6). As shown Figure 6A–B, the pathological
findings revealed less vacuolar degeneration in the MSC group
compared with the Control group. However, these pathological
changes had almost completely improved 168 h after reperfu-
sion, as the H&E-stained liver tissues were no longer
morphologically distinguishable between the two groups (data
not shown).
Figure 2. Characterization of BM-MSCs. BM-MSCs at passage 5 are induced to differentiate into adipocytes, osteoblasts, and chondrocytes-like
cells. Cells analyzed by cytochemical staining with Oil Red-O, Alizarin red, or Safranin-O, respectively.
doi:10.1371/journal.pone.0019195.g002
Figure 3. Decrease of luciferase activity. The expression level of luciferase was postoperatively observed using a noninvasive living image
acquisition IVIS system. Accumulation of MSCs in the remnant liver. A. Most of the MSCs became trapped in the remnant liver. Thereafter, the
luciferase activity diminished with time. B. The largest level of luciferase was 1872726119507 photons/sec/cm
2/sr (sr=units of solid angle or
steradian). (24 h vs. 168 h: P,0.03; 24 h vs. 120 h: P,0.05; 72 h vs. 168 h: P,0.05).
doi:10.1371/journal.pone.0019195.g003
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liver regeneration rate. As shown in Figure 7, the liver
regeneration rate in the MSC group was significantly increased
168 h after reperfusion compared with the Control group
(P,0.03).
Discussion
BM-MSCs have the capacity for self-renewal and multipotency,
and can differentiate into bone, fat and cartilage cells [9,10]. Cell-
based therapy has recently been considered a prominent tool in
regenerative medicine. However, the use of embryonic stem cells
or induced pluripotent stem cells is ethically controversial and can
also result in teratoma formations that hinder the applications of
stem cell therapy. One way to circumvent these issues is to use
MSCs, as they are an attractive alternative for regenerative
medicine.
In recent years, MSC transplantation has been broadly used in
animal models of cerebral infarction, myocardial infarction, and
renal I/R injury to regenerate damaged tissues. Some reports have
published the effectiveness of MSC transplantation against drug-
induced liver injury [4,5]. However, the effectiveness of MSC
transplantation against hepatic I/R injury remains unknown.
Hepatic I/R injury results in pathological changes such as
congestion, vacuolization, and apoptosis in liver tissue, which
can lead to hepatic failure.
Figure 4. Minimal TUNEL-positive hepatocytes by BM-MSC transplantation. TUNEL staining of I/R-injured liver sections from the MSC
group (A. upper panel) and the Control group (B. lower panel). C. Quantification of TUNEL-positive hepatocyte nuclei was assessed by calculating the
mean of the number of TUNEL-positive hepatocytes in 10 random high-power fields per animal. Abbreviations: CV, central vein; PV, portal vein.
doi:10.1371/journal.pone.0019195.g004
Figure 5. LacZ-positive BM-MSCs distributed around the periportal area. Photomicrograph of liver sections stained with X-gal from a rat
6 h after reflow. A. LacZ-positive MSCs (blue) detected around the periportal area. B. MSCs detected in the sinusoid (right panel).
doi:10.1371/journal.pone.0019195.g005
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the Pringle maneuver or by liver transplantation with small-for-
size grafts can be reduced by minimizing hepatic I/R injury and
avoiding the progress of harmful events following I/R injury.
New animal model
In the present study, our rat model provided the ideal animal
model to research I/R injury after major hepatectomy by the
Pringle maneuver or liver transplantation with small-for-size
grafts. Intestinal congestion was avoided during the application
of hepatic ischemia by bypassing portal flow through nonischemic
lobes (right and caudate lobes). Moreover, the left lateral and the
left portion of the medial lobes as well as the nonischemic lobes
were excised at the onset of reflow to mimic the clinical condition
of liver transplantation with small-for-size grafts or major
hepatectomy by the Pringle maneuver in order to research
postischemic liver functions.
The optimal route of transplantation and the optimal
number of MSCs
We selected the portal vein as the route for MSC transplan-
tation. Systemically transplanted MSC photons were monitored
using IVIS
TM, and were mostly trapped in the microvasculature of
the lung because of their size and adhesion potential. Moreover,
the MSC-derived photons from the lung faded out within 1 day,
and no photons in the I/R-injured liver were detected (data not
shown). It is unlikely that recirculating MSCs after pulmonary
trapping migrated to the I/R-injured liver. Thus, the systemic
route is not always considered the best route for MSC
transplantation despite the migration potential of MSCs. A better
method for MSC delivery to the liver might be through the portal
vein.
The optimal number of MSCs is a critical factor, yet little is
known about the optimal cell dose. Most reports have used doses
of 2 to 10 million MSCs per kilogram in small animal experiments
[11]. Some reports have shown that the greater the dose of MSCs
transplanted, the greater the therapeutic effect that is achieved.
However, the maximum dose in rats and mice is determined by
the number of cells that do not undergo fatal embolism by
transplantation (usually not more than 10 million cells overall).
Figure 6. Histopathological changes and Suzuki Score. Hematoxylin eosin staining of I/R-injured liver sections from the MSC group (A. left
panel) and the Control group (B. right panel). C. The lower levels of congestion, vacuolization, and necrosis were seen in the MSC group. Suzuki
scores=(MSC group vs. Control group: 1.461.3 vs. 3.961.7, p,0.03).
doi:10.1371/journal.pone.0019195.g006
Figure 7. Remnant liver volume changes. The liver regeneration
rate is expressed as remnant liver weight/estimated whole liver weight.
doi:10.1371/journal.pone.0019195.g007
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In a model of drug-induced chronic liver disease, a previous
report has shown that transplanted MSCs can be involved in anti-
fibrotic effects. The authors also showed that transplanted MSCs
scattered mostly in the hepatic connective tissue and survived in
the liver 4 weeks after transplantation, but did not differentiate
into hepatocytes expressing albumin or alpha-fetoprotein [5]. This
report suggested that a variety of bioactive cytokines secreted by
the transplanted MSCs might be involved in restoring liver
function and promoting regeneration. In addition, another report
has shown that MSC-conditioned medium has the potential to
dramatically reduce cell death [12,13].
On the other hand, certain studies have described the
transdifferentiation of MSCs into cells with a hepatocyte-like
phenotype [14,15,16,17]. Models of chronic liver disease have a
relatively long time for the onset of cell therapy effects to be
established, and the period of observation is also relatively
longer after the MSCs are transplanted. It is still controversial
whether transplanted MSCs protect and regenerate the liver
by cell fusion or by transdifferentiation, or by neither. Thus,
further studies on the fate of MSCs after transplantation are
necessary.
In models of acute liver disease due to I/R injury, free radicals
generated during the acute phase of I/R injury initiate the
inflammatory cascade, giving rise to the second attack, which is
characterized by infiltration of activated neutrophils in the liver
promptly after reperfusion. Activation of Kupffer cells and T
lymphocytes promotes neutrophil recruitment, assisted by
increased endothelial expression of adhesion molecules. There-
fore, transplanted MSCs need to work efficiently shortly after
reperfusion. In the present study, MSC treatment ameliorated the
increase in serum transaminase levels, which serves as the most
sensitive marker for clinical and experimental hepatic I/R injury
evaluation. These findings indicate that MSCs were viable and
able to function shortly after transplantation. There is limited
time for MSCs to transdifferentiate into hepatocytes or
hepatocyte-like cells during the acute phase. Therefore, it is
unlikely that transdifferentiation is involved in tissue protection
and repair.
Histopathological findings showed that hepatocyte apoptosis
induced by I/R injury mainly existed in the centrilobular region
in the Control group, whereas LacZ-positive MSCs were detected
in the periportal area in the MSC group. Transplanted MSCs did
not replace damaged hepatocytes, but settled down in the
periportal area. This evidence supports the notion that paracrine
actions exerted by MSCs through the release of soluble factors
might be important for tissue protection and repair. Moreover,
the luciferase activity of MSCs gradually decreased and at 168 h
after reperfusion, we could not find any LacZ-positive cells in the
liver sections (data not shown). Once the liver fully recovers, it is
possible that host hepatocytes identify the transplanted MSCs as
non-self cells and eliminate them from the liver. Seventy-two
hours after reperfusion, a degree of liver injury was improved in
the MSC group compared to the Control group. It seems
reasonable that MSC transplantation attenuating I/R injury
would result in the histopathological differences observed
between the MSC group and the Control group. Also, the
sequence of events might affect liver regeneration and cause a
significant difference in remnant liver regeneration 168 h after
reperfusion.
In conclusion, these findings suggest that MSCs might have the
potential to protect the liver against I/R injury-induced hepato-
cyte apoptosis, and to enhance liver regeneration.
Materials and Methods
Animal
All experiments were conducted under the approval of the Jichi
Medical University Guide for Laboratory Animals (Approval
number: # 1080).
Male wild Lewis rats were purchased from Charles River
(Breeding Laboratories, Kanagawa, Japan). Rats used in the
experiments had a body weight of between 230 and 310 g.
The animals were housed in a temperature- and humidity-
controlled environment with a 12 h light/12 h dark cycle with free
access to food (standard laboratory chow) and water ad libitum.
After fasting overnight, all animals were anesthetized with ether
inhalation.
Establishment of double transgenic rats
Double transgenic (Tg) rats expressing luciferase and LacZ were
created by crossbreeding ROSA/luciferase Tg Lewis rats [18]
with ROSA/LacZ Lewis rats [19]. IVIS was used to detect
luciferase expression, and X-gal staining was used to detect LacZ
expression (detailed below). The F1 hybrids between ROSA/
luciferase Tg and ROSA/LacZ Lewis rats were imaged after
intravenous injection of D-luciferin (30 mg/kg/body weight)
(potassium salt; Bio-synth, Postfach, Switzerland), followed by X-
gal staining. In the same manner, luciferase and LacZ expression
levels were examined in various tissues of the rats. Approximately
one-fourth of the F1 hybrids expressed luciferase and LacZ in the
whole body. We used these ‘‘dual colored’’ F1 hybrids expressing
both luciferase and LacZ (luc/LacZ) as our MSC donors.
Bone marrow-derived MSC preparation and culture
Bone marrow cells were isolated from female double (luc/LacZ)
Tg rat femurs by flushing the femurs with aMEM (invitorgen,
Tokyo) supplemented with 10% fetal bovine saline (invitrogen,
Tokyo) and antibiotic-antimycotic (invitrogen, Tokyo), using a 19-
gauge needle. Isolated bone marrow cells were seeded onto 10-ml
tissue culture dishes (Thermo Scientific, Tokyo), and cultured with
aMEM supplemented with 10% FBS. When the cells were 70%–
80% confluent, they were harvested with 0.05% trypsin-EDTA
(invitrogen, Tokyo), replated at 2610
4 cells/cm
2, and cultured for
5 days. MSCs between the fifth and eighth passage were used for
the experiments.
Operative procedure
A temporary warm ischemia of the liver was induced as shown
in Figure 8. All surgical procedures were performed under light
ether anesthesia. The abdomen was opened through a midline
incision and ligaments surrounding each lobe were then dissected
away. Clamping the portal vein, the hepatic artery, and the bile
duct supplying the median and the left lateral lobes of the liver
with a microvessel clip induced 70% partial liver ischemia. This
technique enabled us to avoid intestinal congestion, which may
lead to fatal hemodynamic instability [20,21]. After 40 min of
partial hepatic ischemia, the vessel clip was released to initiate
hepatic reperfusion. Immediately after onset of reperfusion, the
nonischemic lobes (the superior right lateral, the inferior right
lateral, the anterior caudate and the posterior caudate lobes) were
excised. Furthermore, these procedures were followed by left
lateral and left portion of the medial lobectomy, leaving only the
ischemic right portion of medial lobe behind. Subsequently,
phosphate-buffered saline (PBS) or 1610
6 MSCs in a volume of
200 ml were transfused into the portal vein with a 30-gauge needle
for over 1 min. The abdomen was closed with 3-0 silk sutures, and
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food and water.
Animals were sacrificed after the reperfusion of 6, 24, 72, and
168 h (n=6 per each point). Blood samples were taken from the
inferior vena cava for liver function tests, and the liver was
harvested and weighed. Liver tissue samples were collected and
properly preserved for subsequent procedures.
Immunofluorescence
Cells were fixed in 4% formaldehyde for 10 min, followed by
incubation with Protein Block for 30 min. Bone marrow-derived
MSCs were analyzed by immunohistochemistry using monoclonal
anti CD29 (VMRD, Inc., USA), CD31 (santa cruz biotechnolog,
Inc., USA), CD34 (R&D Systems, USA), and CD105 (santa cruz
biotechnology, USA) antibodies overnight at 4uC [22,23]. The
fluorescein (green, 1:3000)-conjugated secondary antibody
(COSMO BIO, Inc., Tokyo) against CD31, CD34, and CD105
was applied for 30 min. Rhodamine (red, 1:3000)-conjugated
secondary antibody (Rockland immunochemicals, Inc., Tokyo)
against CD29 was also used.
Evaluation of the mesenchymal lineage differentiation of
MSCs
The differentiation potential of MSCs (passage 5) into
adipocytes, osteocytes, or chondrocytes was evaluated using
differentiation-induction media purchased from Lonza Walkers-
ville, Inc. (http://www.lonza.com) according the manufacturer’s
protocols.
Detection and quantification of transgene expression
using a non-invasive in vivo imaging system
In Vivo Imaging System IVIS
TM (Xenogen, Allameda, CA) was
used for the analysis of luciferase gene expression activity. In this
system, a noninvasive charged-couple device camera was used to
detect bioluminescene emitted from D-luciferin, which reacts with
firefly luciferase in living animals. While under isoflurane
anesthesia, the rats received D-luciferin through the penile vein
[30 mg/kg/body weight, dissolved and diluted to 15 mg/ml in
PBS] [24]. Immediately after the infusion, the light emitted by
luciferase was measured, with a 1-min integration time. The signal
intensity was quantified as photon flux in units of photons/sec/
cm
2/steradian in the region of interest [25]. The results show the
mean values of 3 rats in each of 6, 24, 72, 120, and 168 h after
reperfusion.
Assessment of liver functions
Blood samples were obtained from each rat and centrifuged for
10 min at 3,000 rpm, and serum was collected. Concentration of
markers of liver injury such as GOT and GPT was analyzed using
a FUJIFILM DRI-CHEM 3500 machine (FujiFilm, Tokyo, Japan;
http://www.fujifilm.co.jp) and FUJI DRY CHEM SLIDES
(FujiFilm), respectively, for GOT/asparatate aminotransferase
(AST)-PIII and GPT/alanine transaminase (ALT)-PIII.
Histological analysis
After euthanasia, livers were fixed with 10% buffered formalin
for paraffin embedding, or in OCT compound for frozen sections
with no fixation. Five-micron paraffine-embedded sections were
stained with hematoxyline and eosin (H&E) for conventional
morphological evaluation. Suzuki classification [26], which
consisted of 3 parameters of hepatic ischemia reperfusion injury:
sinusoidal congestion, vacuolization of hepatocyte cytoplasm, and
parenchymal necrosis. Each parameter was graded numerically as
follows: congestion: 0=none, 1=minimal, 2=mild, 3=moder-
ate, and 4=severe. The same criteria were utilized in the
graduation of the vacuolization, and for necrosis, the numerical
graduation was as follows: 0=nonnecrotic cells, 1=single cell
Figure 8. A new rat model of major hepatectomy with I/R injury.
doi:10.1371/journal.pone.0019195.g008
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necrosis.
Immunohistochemical detection of LacZ-positive cells
and apoptosis
To detect injected LacZ-positive MSCs in the liver, the
experimental rats were sacrificed 6 h after reperfusion. Thin
frozen sections (10 mm) of the liver were fixed in 0.2%
glutaraldehyde for 10 min at room temperature and incubated
in a solution (X-gal) containing 1 mg/ml 5-bromo-4-chloro-3-
indolyl b-D-galactopyranoside (X-gal; Sigma-Aldrich, USA),
5m MK 3Fe(CN)6, 5 mM K4Fe(CN)6, and 2 mM MgCl2 in PBS
at 37uC for 20 h.
Paraffin sections of livers sacrificed 6 h after reflow were
prepared. Apoptosis was determined by in situ detection of DNA
fragmentation using terminal deoxynucleotidyl transferase-medi-
ated 29-deoxyuridine 59-triphosphate nick-end labeling (TUNEL)
assay. Quantification of TUNEL-positive hepatocyte nuclei was
assessed by calculating the mean of the number of TUNEL-
positive hepatocytes in 10 random 2006fields per animal.
Liver regeneration rate
To estimate the recovery rate of rat liver weight after partial
hepatectomy, the resected liver was weighed at the time of partial
hepatectomy, and when the rats were sacrificed the remnant liver
was excised and weighed. The liver regeneration rate was
expressed as remnant liver weight/estimated whole liver weight.
The original whole liver weight was extrapolated by calculating
the resected liver weight/0.663, based on the results of a pilot
study that the resected liver weight in our model was equal to
66.3% of the original whole liver weight (66.365.5%, n=6).
Statistical analysis
The results are given as the mean 6 SD. Statistical analysis was
conducted using the student t-test for continuous data and the
Mann-Whitney test for discontinuous data. A P value of ,0.05
was considered to be statistically significant.
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